12 September 2022 - Nuvaxovid is now authorised in the EU for use in adults aged 18 and older as a booster regardless of previous vaccine history.
Novavax today announced that the European Commission has approved the expanded conditional marketing authorisation of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in the European Union as a homologous and heterologous booster for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for adults aged 18 and older.